
The 36 000-square-meter facility is expected to reach full capacity for insulin active ingredient production in 2032, subject to approvals.
Sanofi has begun construction of a new insulin production unit at its BioCampus in Frankfurt, Germany. The company said the 36 000-square-meter facility is planned to reach full capacity for insulin active ingredient production in 2032, subject to required approvals.
Sanofi said the unit will use advanced digital technologies and artificial intelligence in production and quality control. Once operational, it is expected to become one of Europe’s largest and most advanced insulin production units.
The company announced the project in August 2024. In September 2026, the European Commission approved public support for it from Germany’s federal government, Hesse and Frankfurt under EU state-aid rules.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.